Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 2/20 | 0.36 |
| ▸ | CTSC | P53634 | 1/20 | 0.35 |
| ▸ | REN | P00797 | 2/20 | 0.35 |
| ▸ | ERAP2 | Q6P179 | 8/20 | 0.34 |
| ▸ | ERAP1 | Q9NZ08 | 7/20 | 0.34 |
| ▸ | LNPEP | Q9UIQ6 | 7/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | FCER2 | P06734 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 2/20 | 0.32 |
| ▸ | IL1RN | P18510 | 2/20 | 0.32 |
| ▸ | GHSR | Q92847 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | NPY4R | P50391 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29384685 | 0.97 | ECE1 (0.37) | ECE1CTSCRENERAP2ERAP1 | |
| SCHEMBL29517172 | 0.90 | ERAP2 (0.35) | ECE1RENERAP2ERAP1LNPEP | |
| SCHEMBL31020879 | 0.90 | ACE (0.38) | ECE1RENERAP2ERAP1LNPEP | |
| SCHEMBL78173 | 0.88 | ACE (0.36) | ECE1CTSCDPP4FAPDPP8 | |
| SCHEMBL79320 | 0.88 | ACE (0.36) | ECE1CTSCDPP4FAPDPP8 | |
| SCHEMBL78174 | 0.88 | ACE (0.36) | ECE1CTSCDPP4FAPDPP8 | |
| SCHEMBL30129742 | 0.88 | ECE1 (0.43) | ECE1CTSC | |
| SCHEMBL29881377 | 0.87 | CTSD (0.35) | ECE1CTSCLNPEPANPEP | |
| SCHEMBL16359592 | 0.87 | ACE (0.39) | ECE1ERAP2ERAP1LNPEPMMP1 | |
| SCHEMBL3750892 | 0.86 | MME (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197815-A1 | METHODS AND COMPOSITIONS FOR IMPROVING VISUAL FUNCTION IN OCULAR DISEASES AND DISORDERS | ONL THERAPEUTICS, INC. | 2024-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197815-A1 | METHODS AND COMPOSITIONS FOR IMPROVING VISUAL FUNCTION IN OCULAR DISEASES AND DISORDERS | PDE6C, UACA, EYA3 | ECE1 2169/4885CTSC 457/4885REN 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.